Constipation - A difficult therapeutic problem;Zaparcie stolca - Trudny problem leczniczy

Przeglad Gastroenterologiczny

Volumn 7, Issue 5, 2012, Pages 249-263

  Dzierzanowski, Tomasz ^a,b   Rydzewska, Grazyna ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Klinika Chorób Wewn trznych i Gastroenterologii CSK MSW W Warszawie   (Poland)

Author keywords

Constipation; Opioids; Palliative care

Indexed keywords

OPIATE; OPIATE ANTAGONIST;

CONSTIPATION; DIET; HUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PROPHYLAXIS; REVIEW; TREATMENT PLANNING;

EID: 84870351902     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2012.32063     Document Type: Review

References (90)

1. Szczeklik A. Choroby wewnȩtrzne. Medycyna Praktyczna 2012.
2. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003; 349: 1360-8.
3. Bharucha AE, Wald A, Enck P, Rao S. Functional anorectal disorders. Gastroenterology 2006; 130: 1510-8.
4. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
5. Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006; 10: 209-17. (Pubitemid 43255207)
6. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12: 371-83.
7. Herz MJ, Kahan E, Zalevski S, et al. Constipation: a different entity for patients and doctors. Fam Pract 1996; 13: 156-9. (Pubitemid 26131442)
8. Dzierżanowski T, Ciałkowska-Rysz A, Jarosz J. Ocena dostȩpnych narzȩdzi diagnostycznych zaparcia stolca u pacjentów objȩtych opieka̧ paliatywna̧. Med Paliat 2010; 2: 81-91.
9. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12: 371-83.
10. Ashraf W, Park F, Lof J, Quigley EM. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am J Gastroenterol 1996; 91: 26-32. (Pubitemid 26026032)
11. Dzierżanowski T, Ciałkowska-Rysz A. Ocena przydatności definicji zaparcia stolca u chorych objȩtych opieka̧ paliatywna̧ według Polskiego Towarzystwa Medycyny Paliatywnej. Med Paliat 2011; 1: 33-8.
12. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005; 100 Suppl 1: S1-4.
13. Bytzer P, Howell S, Leemon M, et. Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15 000 Australian adults. Gut 2001; 49: 66-72.
14. Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 2008; 8: 5.
15. Clark K, Smith JM, Currow DC. The prevalence of bowel problems reported in a palliative care population. J Pain Symptom Manage 2012; 43: 993-1000.
16. Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med 2003; 17: 310-4. (Pubitemid 36748433)
17. Rao SS, Sadeghi P, Beaty J, Kavlock R. Ambulatory 24-hour colonic manometry in slow-transit constipation. Am J Gastroenterol 2004; 99: 2405-16. (Pubitemid 40039372)
18. Yu CS, Kim HC, Hong HK, et al. Evaluation of myenteric ganglion cells and interstitial cells of Cajal in patients with chronic idiopathic constipation. Int J Colorectal Dis 2002; 17: 253-8. (Pubitemid 36075780)
19. Xiao ZL, Pricolo V, Biancani P, Behar J. Role of progesterone signaling in the regulation of G-protein levels in female chronic constipation. Gastroenterology 2005; 128: 667-75. (Pubitemid 40585369)
20. Gershon MD. Serotonin receptors and transporters: roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004; 20 Suppl 7: 3-14. (Pubitemid 39657670)
21. Attaluri A, Jackson M, Valestin J, Rao SS. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol 2010; 105: 1407-11.
22. Karasick S, Ehrlich SM. Is constipation a disorder of defecation or impaired motility? Distinction based on defecography and colonic transit studies. AJR Am J Roentgenol 1996; 166: 63-6. (Pubitemid 26010222)
23. Rao SS, Tuteja AK, Vellema T, et al. Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol 2004; 38: 680-5. (Pubitemid 39096799)
24. Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol 1998; 93: 1042-50. (Pubitemid 29080947)
25. Rao SS. Dyssynergic defecation and biofeedback therapy. Gastroenterol Clin North Am 2008; 37: 569-86.
26. Rao SS, Kavlock R, Rao S. Influence of body position and stool characteristics on defecation in humans. Am J Gastroenterol 2006; 101: 2790-6. (Pubitemid 44902652)
27. Cash BD, Chey WD. Diagnosis of irritable bowel syndrome. Gastroenterol Clin North Am 2005; 34: 205-20. (Pubitemid 40615951)
28. Dzierżanowski T, Jarosz J. Zaparcia u chorych leczonych opioidami. Onkol Prakt Klin 2009; 2: 47-54.
29. Dzierżanowski T, Ciałkowska-Rysz A. Wpływ czynników ryzyka na wystȩpowanie zaparcia stolca u pacjentów objȩtych opieka̧ paliatywna̧. Med Paliat 2010; 4: 209-13.
30. Rao SS, Ozturk R, Laine L. Clinical utility of diagnostic tests for constipation in adults: a systematic review. Am J Gastroenterol 2005; 100: 1605-15. (Pubitemid 41032371)
31. Qureshi W, Adler DG, Davila RE, et al. ASGE guideline: guideline on the use of endoscopy in the management of constipation. Gastrointest Endosc 2005; 62: 199-201. (Pubitemid 41021541)
32. Evans RC, Kamm MA, Hinton JM, Lennard-Jones JE. The normal range and a simple diagram for recording whole gut transit time. Int J Colorectal Dis 1992; 7: 15-7.
33. Ghoshal UC, Sengar V, Srivastava D. Colonic transit study technique and interpretation: can these be uniform globally in different populations with non-uniform colon transit time? J Neurogastroenterol Motil 2012; 18: 227-8.
34. Librach SL, Bouvette M, De Angelis C, et al.; Canadian Consensus Development Group for Constipation in Patients with Advanced Progressive Illness. Consensus recommendations for the management of constipation in patients with advanced, progressive illness. J Pain Symptom Manage 2010; 40: 761-73.
35. Tsubouchi T, Saito T, Mizutani F, et al. Stimulatory action of itopride hydrochloride on colonic motor activity in vitro and in vivo. J Pharmacol Exp Ther 2003; 306: 787-93. (Pubitemid 36886181)
36. Lim HC, Kim YG, Lim JH, et al. Effect of itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro. Yonsei Med J 2008; 49: 472-8.
37. Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology 2005; 129: 86-97. (Pubitemid 41002045)
38. Battaglia E, Serra AM, Buonafede G, et al. Long-term study on the effects of visual biofeedback and muscle training as a therapeutic modality in pelvic floor dyssynergia and slow-transit constipation. Dis Colon Rectum 2004; 47: 90-5. (Pubitemid 38040251)
39. Lucero M, Von Scheele B, Blackard R, et al. The incidence and impact of gastrointestinal adverse events (GIAEs) associated with opioid analgesic use: a review of the literature. J Pain 2006; 7: S89.
40. Annunziata K, et al. Constipation is a predominant side effect of opioid treatment for persistent pain. J Pain 2006; 7: S89.
41. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182 (5A Suppl): 11S-8S.
42. Yuan C. Handbook of opioid bowel syndrome. Medical Press, New York 2005.
43. Sands M, Piza M, Ingham J. The epidemiology of the end-of-life experience. Oxford Texbook of Palliative Medicine 2010; 58-80.
44. van den Beuken-van Everdingen M, de Rijke J, Kessels A, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-49.
45. World Health Organization. Cancer pain relief. (2 ed.). WHO, Geneva 1995.
46. Caraceni A, Hanks G, Kaasa S, et al.; the European Palliative Care Research Collaborative (EPCRC)on behalf of the European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology 2012; 13: e58-68.
47. Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage 1990; 5: 362-7.
48. Davis M, Pasternak G. Opioid receptors and opoid pharmacodynamics. Opioids in cancer pain. 2nd Ed. Oxford University Press 2009; 1-29.
49. Sweeney C, Bogan C. Assessment and management of opioid side effects. Textbook of palliative medicine. Hodder Arnold 2009; 390-401.
50. Kromer W. Reflex peristalsis in the guinea pig isolated ileum is endogenously controlled by kappa opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 1990; 341: 450-4. (Pubitemid 20154558)
51. Shahbazian A, Heinemann A, Schmidhammer H, et al. Involvement of micro- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br J Pharmacol 2002; 135: 741-50. (Pubitemid 34177652)
52. Allescher HD, Storr M, Brechmann C, et al. Modulatory effect of endogenous and exogenous opioids on the excitatory reflex pathway of the rat ileum. Neuropeptides 2000; 34: 62-8. (Pubitemid 30164284)
53. Kaufman PN, Krevsky B, Malmud LS, et al. Role of opioid receptors in the regulation of colonic transit. Gastroenterology 1988; 94: 1351-6.
54. Galligan JJ, Burks TF. Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat. J Pharmacol Exp Ther 1983; 226: 356-61. (Pubitemid 13041507)
55. Porreca F, Mosberg HI, Hurst R, et al. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 1984; 230: 341-8. (Pubitemid 14061610)
56. Leppert W, Dzierżanowski T, Ciałkowska-Rysz A, et al. Postȩpowanie u chorych z zaparciem stolca w medycynie paliatywne - zalecenia Grupy Roboczej Ekspertów Polskiego Towarzystwa Medycyny Paliatywnej. Med Paliat 2009; 1: 1-10.
57. Dzierżanowski T, Ciałkowska-Rysz A. Ocena przydatności definicji zaparcia stolca u chorych objȩtych opieka̧ paliatywna̧ według Polskiego Towarzystwa Medycyny Paliatywnej. Med Paliat 2011; 1: 33-8.
58. Leppert W, Majkowicz M. Ocena analgezji i objawów niepoża̧danych tramadolu i dihydrokodeiny o kontrolowanym uwalnianiu u chorych z bólem nowotworowym - na podstawie zmodyfikowanej skali ESAS. Wspolczesna Onkol 2008; 12: 246-54.
59. Grond S. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manag 2003; 18: 174-9.
60. Wilder-Smith CH, Hill L, Osler W, O'Keefe S. Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig Dis Sci 1999; 44: 1107-16. (Pubitemid 29297212)
61. Mucci-LoRusso P, Berman BS, Silberstein PT, et al. Controlled-release oxycodone compared with controlled release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 1998; 2: 239-49. (Pubitemid 28474354)
62. Payne R, Mathias SD, Pasta DJ, et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16: 1588-93. (Pubitemid 28175785)
63. Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004; 20: 1419-28. (Pubitemid 39361345)
64. Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in long-term control of chronic pain in cancer patients. Front Biosci 2007; 12: 1291-9. (Pubitemid 46846834)
65. Kalso E, Heiskanen T, Rantio M, et al. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain 1996; 67: 443-9. (Pubitemid 26375362)
66. Drexel H, Dzien A, Spiegel RW, et al. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 1989; 36: 169-76. (Pubitemid 19045575)
67. Ueberall MA, Mueller-Schwefe G. Opioid-induced constipation - a frequent and distressing side effect in daily practice affecting oral and transdermal opioid applications. Eur J Pain 2006; 10: S172.
68. Staats P, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J 2004; 97: 129-34. (Pubitemid 38222814)
69. Dzierżanowski T. Wpływ obcia̧żenia opioidami na skuteczność zastosowania metylonaltreksonu u pacjentów z zaparciem stolca w zaawansowanym stadium choroby nowotworowej. Praca doktorska. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie 2011.
70. Mercadante S, Villari P, Ferrera P, Casuccio P. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? Eur J Pain 2006; 10: 153-9. (Pubitemid 41727765)
71. Irving G, Hermanns K, Cousins M, et al. Gastrointestinal adverse events (GIAEs) associated with long-term opioid analgesic therapy in a large, persistent non-cancer pain population. J Pain 2006; 7: S89.
72. Ueberall MA, Mueller-Schwefe G. Opioid-induced constipation - a frequent and distressing side effect in daily practice affecting oral and transdermal opioid applications. Eur J Pain 2006; 10: S172.
73. Bell T, Milanova T, Grove G, et al. OBD symptoms impair quality of life and daily activities, regardless of frequency and duration of opioid treatment: Results of a US patient survey (PROBE survey). J Pain 2007; 8: S71.
74. Cook S, Bell T, Sweeney C, et al. Impact on quality of life of constipation-associated GI symptoms related to opioid treatment in chronic pain patients: PAC-QOL results from the opioid survey. J Pain 2007; 8: S71.
75. Annunziata K, Bell T. Impact of opioid-induced constipation on healthcare resource utilisation and patient functioning. Eur J Pain 2006; 10: S172.
76. Bell T, Annunziata K, Freedman D, et al. Opioid-induced constipation increases healthcare resource use and impairs work productivity: comparison with other patient groups with and without constipation. Eur J Pain 2006; 10: S75.
77. Thompson K, Adams A, Wee B. The burden of constipation. EAPC 11th Congress, Vienna, Austria, 7-10 May 2009; poster S433.
78. Goodman M, Low J, Wilkinson S. Constipation management in palliative care: a survey of practices in the United Kingdom. J Pain Symptom Manage 2005; 29: 238-44. (Pubitemid 40386740)
79. Max EK, Hernandez JJ, Sturpe DA, Zuckerman IH. Prophylaxis for opioid-induced constipation in elderly long-term care residents: a cross-sectional study of medicare beneficiaries. Am J Geriatr Pharmacother 2007; 5: 129-36. (Pubitemid 47277276)
80. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 649-71. (Pubitemid 36408072)
81. Dzierżanowski T, Ciałkowska-Rysz A. Oksykodon - lek pierwszego rzutu w leczeniu silnego bólu nowotworowego. Med Paliat 2010; 3: 123-31.
82. Meissner W, Schmidt U, Hartmann M, et al. Oral naloxone reverses opioid-associated constipation. Pain 2000; 84: 105-9.
83. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008; 24: 3503-12.
84. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid- induced constipation. Eur J Pain 2009; 13: 56-64.
85. Nadstawek J, Leyendecker P, Hopp M, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract 2008; 62: 1159-67. (Pubitemid 351977620)
86. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008; 9: 1144-54.
87. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010; 64: 763-74.
88. Smith K, Hopp M, Mundin G, et al. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther 2008; 30: 2051-68.
89. Dzierżanowski T, Ciałkowska-Rysz A. Czy możliwe jest leczenie opioidem bez wywoływania zaburzeń przewodu pokarmowego? Zastosowanie preparatu złożonego oksykodonu w poła̧ czeniu z naloksonem w świetle dowodów klinicznych. Med Paliat 2011; 3: 121-8.
90. Yuan CS, Israel RJ. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs 2006; 15: 541-52.